MD Anderson Registers Relatlimab·Ipilimumab·Nivolumab Triple Combination Phase 1/2a Trial
Blocking Three Immune Checkpoints Simultaneously
The University of Texas MD Anderson Cancer Center has registered a Phase 1/2a clinical trial (NCT06683755) for first-line treatment of metastatic melanoma. The investigational regimen combines Opdivo (nivolumab, PD-1), Yervoy (ipilimumab, CTLA-4), and relatlimab-rmbw (LAG-3) in a triple-combination approach. The strategy aims to simultaneously release different T-cell inhibitory signals to enhance response depth and durability, although the combination itself is still in the investigational phase and not FDA approved.
A Dose-Exploration Trial for 30 Patients
According to ClinicalTrials.gov, the trial is a single-center interventional study involving 30 adult participants. Phase 1 and 2a will be conducted consecutively. As of the latest update on November 12, 2024, the trial is still recruiting, with an estimated start date of May 1, 2025, and a primary completion date of August 16, 2030. Phase 1 will determine the recommended Phase 2a dose (RP2D) of ipilimumab, while Phase 2a will assess initial efficacy using objective response rate (ORR) per RECIST 1.1. Progression-free survival (PFS), overall survival (OS), safety, and tumor and blood immune biomarkers will also serve as indicators for further development potential.
Targeting the Efficacy-Toxicity Gap Between Approved Dual Therapies
Bristol Myers Squibb (BMY)'s Opdualag (nivolumab·relatlimab) received FDA approval on March 18, 2022, for first-line treatment of unresectable or metastatic melanoma. The approval was based on RELATIVITY-047, which showed a median PFS of 10.1 months compared to 4.6 months in the nivolumab monotherapy group. Opdivo·Yervoy combination therapy also received FDA accelerated approval on September 30, 2015, and is an established standard of care. TRINITY aims to enhance efficacy by adding CTLA-4 blockade to the more manageable LAG-3·PD-1 backbone. The actual development value will depend on whether it can control dose-limiting toxicity (DLT) and immune-related adverse events.
The Competitive Benchmark Is Already High
Key competing therapies include Opdualag, Opdivo·Yervoy, Merck & Co. (MRK)'s Keytruda (pembrolizumab, PD-1), and BRAF·MEK-targeted combination therapy for BRAF V600-mutant patients. Opdualag is projected to generate $1.185 billion in global sales in 2025, demonstrating that LAG-3-based melanoma treatments have already established a commercial market. Therefore, the 30-patient trial is not a confirmatory comparative trial but a step to select the dose and efficacy signals for subsequent randomized trials. A positive ORR alone will not be sufficient; evidence that the increased toxicity does not offset the clinical benefit compared to existing dual therapies will be necessary.
From an investor perspective, TRINITY offers an early option to expand the Opdualag franchise, which generated $1.185 billion in sales in 2025, into a triple-combination therapy. However, it is currently in a Phase 1/2a trial with only 30 participants. For researchers, the trial is significant because it allows the analysis of tumor tissue and peripheral blood immune changes associated with PD-1·LAG-3·CTLA-4 simultaneous blockade in relation to patient responses. In terms of industry competition, the benchmarks are already at the approved and marketed stages, including Opdualag, Opdivo·Yervoy, Keytruda, and BRAF·MEK combination therapy. Therefore, subsequent development will require not only ORR but also a balanced assessment of PFS, OS, and severe immune-related adverse events. In the short term, the RP2D and safety signals will be key, and in the medium to long term, successful entry into comparative trials could impact Bristol Myers Squibb (BMY)'s melanoma immunotherapy portfolio defense and treatment sequence reorganization.
Source: ClinicalTrials.gov (api_ct)